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WNT5A is a secreted ligand involved in differentiation, proliferation, cell 
movement and apoptosis. WNT5A is often misregulated in cancer and is known to be 
involved in cancer metastasis. The focus of this study was the possible epigenetic 
regulation of WNT5A expression in osteosarcoma cells. I analyzed WNT5A regulation 
from its two major transcription start sites, termed Promoter A and Promoter B. The 
levels of promoter B transcripts were reduced in the osteosarcoma cell line, U20S, and in 
primary osteosarcoma tissue of three individuals, compared to normal osteoblasts. To 
determine if this decrease in Promoter B activity in U20S is due to DNA methylation, I 
analyzed six CpG islands associated with Promoter B by bisulfite sequencing. Results 
show that Regions 1 and 2 are unmethylated, Regions 3, 4, 5 are methylated and Region 
6, which includes the Promoter B start of transcription, is partially methylated.  The DNA 
methylation pattern is similar to the pattern determined in another osteosarcoma cell line, 
SaOS-2. Region 6, however, is only 25% methylated in U20S, whereas 62% methylated 
in SaOS-2. The level of methylation is negatively correlated with Promoter B transcript 
levels, indicating that Region 6 methylation decreases transcription. Histone 
modifications were examined for their involvement in Promoter A and Promoter B 
activity by chromatin immunoprecipitation (ChIP) assays. H3K4me3, an activating 
histone mark, was highly enriched in Promoter A and reduced in Promoter B Region 6 of 
U20S cells, indicating that H3K4me3 has a role in the reduction of Promoter B activity. 
H3K27me3 and H3K9me3, repressive histone marks, were not differentially altered on 
 
 
Promoters A and B. H3K27me3 was enriched on Regions 3 and 4 located upstream of the 
Promoter B start of transcription. Overall, these results suggest that WNT5A Promoter B 
activity is reduced in osteosarcoma as a result of both histone modification and DNA 
methylation. 
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CHAPTER I 
INTRODUCTION 
 
 
The American Cancer Society (2012) estimates that one half of men and one third 
of women in the United States will get cancer. The general feature of many cancers is 
that cells grow uncontrollably and may eventually metastasize. These cellular 
characteristics are caused by genetic and non genetic changes. WNT5A is a gene that is 
often misregulated in cancer by non genetic or epigenetic changes. Significantly, 
WNT5A has been shown to be involved in cancer cell metastasis. The human WNT5A 
gene gives rise to two different protein isoforms due to distinct transcriptional start sites 
(we termed Promoter A and Promoter B). Studies of WNT5A gene methylation mostly 
have focused on the Promoter A region but sequence analysis shows that Promoter B also 
contains CpG islands. The goals of this project were to determine the Promoter A and 
Promoter B transcript levels and to analyze methylation status of the Promoter B 
associated CpG islands in osteosarcoma cells. In addition, specific histone modifications 
associated with WNT5A Promoter A and Promoter B were analyzed. These data suggest a 
mechanism for the alteration of WNT5A expression during cancer progression.  
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WNT5A Signaling  
The Wnts are a family of secreted glycoproteins responsible for regulation of cell 
proliferation, differentiation, cell movement, and apoptosis. Wnt glycoproteins perform 
these functions by interacting with the Frizzled cell surface receptors (Fz) (Clevers, 
2006). Wnt signaling operates through two different pathways, the canonical and non 
canonical. The canonical pathway is a beta-catenin-dependent path that involves Wnt 
protein binding to lipoprotein receptor (Lpr) and the Fz receptor (MacDonald et al.,  
2009). This leads to the recruitment of the “Axin complex” that normally targets beta-
catenin for proteasome degradation (Clevers, 2006). The axin complex includes the 
following proteins: glycogen synthase kinase 3(GSK3), adenomatous polyposis (APC), 
casein kinase 1 (CK1) and axin (MacDonald et al., 2009). Active beta-catenin moves to 
the nucleus and binds to T-Cell factor/lymphoid enhancer factor (Tcf/Lef). This beta-
catenin-Tcf/lef complex acts as a transcription factor activating transcription of target 
genes such as myc (ten Berge et al., 2008) and cyclin D (Sansom et al., 2005). WNT5A 
does not directly signal through the canonical pathway but can negatively affect the 
cannonical beta-catenin pathway (Figure 1).  
 WNT5A signals through the non-canonical pathway. The non-canonical pathway 
involves signaling through the Fz and Ror1/2 receptors and does not lead to beta-catenin 
activation but rather initiates either the RhoA/Rac or calcium (Ca
2+
) pathways. WNT5A 
forms a tertiary complex with the Fz and Ror1/2 receptors. The activated Fz receptor 
leads to phosphorylation of Dishevelled (Dvl). Dvl signals guanosine nucleotide-binding 
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proteins (G proteins), RhoA and Rac. RhoA leads to activation of Rho-kinase and Rac 
leads to activation of JNK (c-Jun N-terminal kinase). Rho kinase and JNK both lead to 
cytoskeletal changes, affecting cell polarity and migration. The other non-canonical 
pathway that WNT5A regulates is the Ca
2+
 pathway. Again, WNT5A binds to the Ror1/2 
and Fz receptors leading to phosphorylation of Dvl. In this pathway, Dvl leads to an 
increase in intracellular Ca
2+
. Ca
2+
 acts as a second messenger that leads to activation of 
protein kinase C (PKC) and calmodulin-dependent protein kinase II (CamKII). CamKII 
blocks beta-catenin signaling by inhibiting the beta-catenin-Tcf/Lef transcription factors 
bound to gene promoters (Kikuchi et al., 2012).  Activation of CamKII and PKC also 
leads to changes in cell migration and invasion (Nishita et al., 2010; Figure 1).  
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Figure 1. WNT5A Signaling Pathways. WNT5A signals through the beta-catenin 
independent pathways. A. The planar cell polarity (PCP)/convergent extension (CE) 
pathway. WNT5A signaling cascades through this pathway to effect cytoskeletal 
changes, cell migrations and cell polarity. B. The Calcium (Ca
2+
) pathway. WNT5A 
signals through this pathway to inhibit to inhibit beta-catenin and gene expression. This 
leads to cell migrations and invasion. CaMK, Ca
2+
/calmodulin-dependent kinase; Dvl, 
disheveled; Fz, Frizzle; PKC, protein kinase C; JNK, c-Jun N-terminal kinase; Tcf/Lef, 
T-cell factor/lymphoid enhancer factor. Based on diagrams in Kikuchi et al. (2012) and 
Nishita et al. (2010).  
 
 
More relevant to this proposal is the signaling interaction between WNT5A and 
osteoblasts.WNT5A activates the non-canonical pathways that can interfere with the 
canonical Wnt signaling in osteoblasts.WNT5A is expressed in osteoblast stem cells and 
Ror2 is expressed in precursor osteoclasts. Mice deficient in WNT5A and Ror2 display 
disruptions in osteoclast production. These results suggest WNT5A is crucial for 
osteoclast generation and osteoclast homeostasis (Maeda et al., 2012). 
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Cellular Functions of WNT5A 
 WNT5A signaling is required in various cell functions related to cell movement, 
including cell adhesion and cytoskeletal rearrangement.WNT5A signaling regulates cell 
adhesion by activating G proteins and other kinases in the cell (See Figure 1). WNT5A 
activates the G protein Rac, which is responsible for regulating the lamellipodium of 
migrating cells. Focal adhesion kinase (FAK) is also regulated by WNT5A. FAK is 
involved in adhesion turnover by controlling microtubule polarization (Kikuchi et al., 
2012; Mitra et al., 2005).  In one study, WNT5A knockdown disrupted cell adhesion, cell 
migration and FAK (Matsumoto et al. 2010).  
 In embryonic fibroblasts, WNT5A induces cell migration via Ror 2. It is proposed 
that the formation of lamellipodium in fibroblasts is mediated by Ror 2 and filamin A 
(FLNa), which is an actin-binding protein. In addition to the lamellipodium formation, 
WNT5A mediates the reorganization of the microtubule organizing center, which 
includes the involvement of Ror 2, FLNa and JNK. APC also functions as a microtubule-
plus-end binding protein that is boosted by WNT5A signaling. Dvl and the APC complex 
bind FAK and paxillin, a focal adhesion molecule. FAK and paxillin are responsible for 
microtubule stabilization around the cell’s leading edge, which is important for cell 
migration (Wong et al., 2003).  
 WNT5A is also involved in mesenchymal cell differentiation. Chondrocytes and 
osteoblasts share common precursor mesenchymal stem cell. WNT5A-deficient mice, 
either die prematurely around childbirth or the mice have truncated limbs and proximal 
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skeletons (Yamaguchi et al., 1999). The researchers of this study determined that the 
death and abnormally shortened limbs were due to a significant decrease in cell 
proliferation. This decrease was due to the absence of WNT5A recruiting mesenchymal 
stem cells, reduced  induction of chondrocyte proliferation, and deregulation of 
hypertrophic stages (Yamaguchi et al., 1999; Yang et al., 2009). It is speculated that 
WNT5A inhibits the beta-catenin pathway in the stem cells to decrease osteogenesis and 
promote chondrogenesis (Bradley and Drissi, 2010).  
WNT5A Gene Structure and Protein Isoforms 
  The human WNT5A gene is located on Chromosome 3, band p14, between 
55,499,744 and 55,521,331 base pairs. The human WNT5A gene has different 
transcription start sites and alternative splicing that generates six transcripts (Ensembl, 
EN5600000114251). These transcripts give rise to four proteins (Table 1). The transcript, 
WNT5A-201 (ENST00000264634) is 5837 base pairs long with 5 exons and 4 introns 
that encodes a protein of 380 amino acids (Figure 2). This transcript is derived from what 
is referred to in the lab as Promoter A (Katula et al., 2012) and is the most studied of the 
WNT5A transcripts. It corresponds to the cDNA RefSeq NM_003392.  Another transcript, 
WNT5A-005, is produced from the transcription start site referred to as promoter B, 
within the first intron of the Promoter A transcription unit (Figure 2). The Promoter B 
transcript encodes a protein of 365 amino acids and is 15 amino acids shorter than the 
derived Promoter A protein. The Promoter A transcript has a unique Exon 1, whereas the 
Promoter B transcript includes a unique Exon 1β (Figure 2). Exons 2, 3, 4 and 5 are 
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common to both transcripts (Bauer et al., 2013). The unique Exon 1 and Exon 1β 
sequences were used to develop Taqman primer-probes specific to Promoter A and 
Promoter B transcripts, respectively (Katula et al., 2012).  
 
Table 1. Human WNT5A Gene Transcripts and Proteins 
1 
 
 
Name Length (basepair) Length (amino 
acids) 
Biotype 
WNT5A-001 6042 380 Protein coding 
WNT5A-201 5837 380 Protein coding 
WNT5A-005 5576 365 Protein coding 
WNT5A- 009 959 214 Protein coding 
WNT5A-007 521 - Processed transcript 
WNT5A-008 661 - Retained intron 
1
 Derived from Ensembl ENST00000264634. The length of the WNT5A-005 transcript 
was updated based on Bauer et al. (2013) 
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Figure 2. WNT5A Gene Transcripts. A. The location of Promoter A and Promoter B 
transcription start sites and exons on Chromosome 3. B. Promoter A and Promoter B 
primary transcripts. Black boxes are coding regions; open boxes are untranslated regions. 
Sizes in nucleotides of the exons and introns are shown in parenthesis. Exon 1 is unique 
to Promoter A; Exon 1β is unique to Promoter B. This diagram is based on the Ensembl 
EN5600000114251 and Bauer et. al, 2013.  
 
 
Until recently, WNT5A studies have focused on the Promoter A transcript and its 
derived protein. In a recent study, Bauer et al. (2013) provide evidence that the protein 
isoforms from transcripts Promoter A and Promoter B are functionally distinct. They 
showed that after processing in the rough endoplasmic reticulum, the Promoter A derived 
protein (termed isoform WNT5A-L) has an additional 18 N-terminal amino acids 
compared to the Promoter B derived protein (termed isoform WNT5A-S). Functional 
analyses indicate that in some cancers, isoform WNT5A-L reduces proliferation, whereas 
isoform WNT5A-S increase cell proliferation. This suggests that differential expression 
of the isoforms could affect cell proliferation. There was no distinction observed between 
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the isoforms with regards to their effects on the beta-catenin Wnt signaling pathway; both 
inhibit the pathway to the same degree.  
WNT5A and Cancer 
 WNT5A levels have been shown to vary in a wide range of cancers such as lung, 
gastric, pancreatic, prostate, osteosarcoma (Huang et al., 2010; Kurayoshi et al., 2006; 
Ripka et al., 2007; Wang et al., 2010; Enomoto et al., 2009). It appears, however, that 
WNT5A can function in some cancers as an oncogene and in others as a tumor 
suppressor. This is supported primarily by the finding that WNT5A can be overexpressed 
or inactivated, depending on the cancer type. There is also some experimental evidence 
that WNT5A has tumor suppressor or oncogenic functions, based primarily on 
overexpression of WNT5A from transfection of expression vectors and siRNA knockout 
studies.  
 Most significantly, high levels of WNT5A expression have been associated with 
metastasizing cancers. WNT5A protein was found to be highly expressed in the leading 
edge of cells in non-melanoma skin cancer (Pourreyron et al., 2012). High levels of 
WNT5A gene expression was detected in invasive pancreatic adenocarcinomas (Bo et al., 
2013). Experimentally, transfection of a WNT5A expression vector lead to increased 
melanoma cell invasion associated with protein kinase C (PKC) activation and increased 
cell invasion (Weeraratna et al., 2002). In osteosarcoma, WNT5A expression promotes 
invasiveness and migrations. In the cell lines, SaOS-2 and U20S, constitutively active 
WNT5A and Ror2 were found to increase actin protrusions, invadopodias and 
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degeneration of the extracellular matrix that is mediated by MMP-13 (Enomoto et al., 
2009). In another study,WNT5A overexpression caused constitutive activation of 
WNT5A-Ror 2 signaling that lead to expression of matrix metalloproteinase (MMP) that 
leads to invasiveness of  prostate cancer cells (Yamamoto et al., 2010). Zhang et al. 
(2014) found that WNT5A promotes migration of human osteosarcoma cells through the 
phosphatidylinositol-3 kinase/Akt signaling pathway.   
 Most WNT5A studies have focused on the Promoter A transcript and protein 
isoform. Our lab and Bauer et al. (2013) provide evidence that WNT5A Promoters A and 
B are differentially regulated in cancer. Bauer et al. (2013) showed that the WNT5A-L 
transcript (Promoter A) is down regulated, whereas the  WNT5A-S transcript (Promoter 
B) is overexpressed in HeLa (cervical), MDA-MB-231 (breast) and SA-SY5Y 
(neuroblastoma) cancer cell lines. These results suggest that WNT5A-S (Promoter B) is 
functioning as an oncogene, whereas WNT5A-L (Promoter A) is a tumor suppressor. 
Contrary to Bauer et al. (2014), we found that WNT5A Promoter B transcripts are nearly 
absent in the osteosarcoma cell line, SaOS-2 (Hsu, 2012), whereas, Promoter A is active. 
Normal osteoblasts were found to produce both transcripts, with Promoter B transcripts at 
a higher level (Hsu, 2012). This suggests that during osteoblast transformation, Promoter 
B is being silenced, indicating it may have tumor suppressor function. 
WNT5A Epigenetic Regulation 
WNT5A misregulation in cancer appears to be due to nongenetic or epigenetic 
changes rather than gene mutation. Epigenetic changes include DNA methylation and 
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histone modifications. DNA methylation involves the addition of a methyl group to the 5 
carbon position on cytosine, usually to CpG dinucleotides, by DNA methyltransferases 
(dnmts). Different DNA methyltransferases are responsible for initiation and maintenance 
of methylated DNA. Normal patterns of genomic DNA methylation are established in 
during early embryogenesis, where nearly all CpGs are methylated. CpG are commonly 
found around promoter regions of genes where DNA methylation is usually associated 
with transcriptional repression.  
WNT5A methylation has been detected in cancer types in which the gene is not 
expressed. In one study, six different colorectal cancer cell lines were tested for their 
level of WNT5A methylation (Ying et al., 2008). In the cell lines with low levels of 
WNT5A expression, they showed total methylation of the WNT5A gene. One cell line 
with moderate levels of WNT5A expression showed weak methylation of WNT5A. The 
sixth cell line with a high amount of WNT5A had no methylation. Also, WNT5A 
expression could be induced by knockout of two dnmts. These results indicate that the 
WNT5A promoter (A) region is methylated in colorectal tumors to reduce its activity and 
that WNT5A methylation is mediated by dnmts (Ying et al., 2008)(Ying et al., 2008).  
In leukemia, WNT5A was also shown to be methylated (Martín et al., 2010). In a 
study on acute myeloid leukemia (AML), they assessed the difference in WNT5A 
expression in seven AML cell lines and bone marrow cells from healthy donors. They 
found that the WNT5A promoter region was methylated in low WNT5A expressing AML 
cell lines and completely unmethylated in healthy bone marrow tissue. These findings 
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indicate that WNT5A expression is modified by DNA methylation during leukemia 
tumorigenesis. It is important to note that the Promoter A genomic region was analyzed 
in these studies.  
Methylation analysis of Promoter B associated CpG’s in osteoblasts and SaOS-2  
osteosarcoma cells was conducted in our lab (Vaidya, 2013). In normal osteoblasts, six 
identified CpG islands were found to be completely unmethylated. In the SaOS-2 cell 
line, the six different CpG islands show different levels of methylation. The most 5’ CpG 
islands nearest to Promoter A, 1 and 2, were totally unmethylated. CpG islands 3, 4, and 
5 were completely methylated.  CpG island 6, which includes the Promoter B 
transcriptional start site and Exon 1β sequences, showed partial methylation with the first 
fifteen CpGs unmethylated and the last eleven CpG methylated. Treatment of SaOS-2 
cells with 1 µM  5-aza-2’deoxycytidine for 72 hours lead to reactivation of Promoter B 
and a slight reduction in methylation in CpG island 6 (Vaidya, 2013). Together, these 
results support the conclusion that the WNT5A Promoter B is inactivated in SaOS-2 cells 
due to DNA methylation. 
It is likely that histone modifications plays a role in the epigenetic regulation of 
WNT5A expression in cancer cells. Histones are proteins involved in packaging DNA 
into chromatin structures within the nucleus, which can be modified to control gene 
expression. Two each of the four  histones, H2a, H2b, H3, H4 associate to form a core 
around 147 base pairs of DNA wraps to form a nucleosome. Modifications of histones 
take place at the amino acid residues on the histone N-terminal tail. Histone 
 
13 
 
modifications alter gene expression by affecting nucleosome structure, which allows for 
repression or expression of a gene. The focus of this research project is the histone 
modification, methylation. Most histone methylation occurs on the lysine and arginine 
amino acids on the histone tail. Methylation can inhibit or activate gene expression 
depending on the location of the amino acid methylation and how many times that amino 
acid is methylated. For example, H3K27me3 (trimethylated on lysine residue 27) is a 
repressive histone mark, whereas H3K4me3 is an activating histone mark (Ekström et al., 
2009).  
DNA methylation and histone modifications have a relationship in regulating 
gene expression. As such, any observed change in DNA methylation would be expected 
to alter histone modifications.  In early development, it has been proposed that histone 
modifications are implemented before de novo methylation. Following fertilization, 
CpG’s become unmethylated across the genome except for imprinted regions. Before de 
novo methylation, histone H3 is methylated at active gene regions to H3K4me. At the 
time of de novo methylation when the embryo implants, the DNA methyltransferases 
Dnmt3 cannot methylate regions that have the H3K4me (Guenther et al., 2007). This 
explains the correlation between the presence of an active histone marker and no DNA 
methylation. DNA methylation is important for maintaining histone modifications after 
DNA replication (Bostick et al., 2007). Chromatin structures are disrupted when the 
replication fork progresses along DNA, after which the DNA methylation pattern is used 
as a marker to reconstruct the histone modifications (Cedar and Bergman, 2009).  
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  Histone modifications have been associated with silencing of WNT5A in certain 
colon cancer cell lines. In this study both a metastatic, SW620, and non-metastatic, 
SW480, colon cancer cell lines were tested for epigenetic alterations (Li & Chen, 2012). 
The cell lines were treated with 5-aza-cytidine but neither cell line showed any change. 
This suggested that WNT5A expression was not caused by the DNA methylation. The 
SW620 cells were treated with the histone deacetylase inhibitors, trichostatin A and 
sodium butyrate, which lead to an increase in WNT5A expression.  ChIP was also to 
detect histone modifications before and after treatment with sodium butyrate. Low levels 
of H3Ac, H4Ac, and H3K4me2 were found in SW620 while high levels of H3K27me3 
were found in SW620 in comparison to SW480. After treatment with sodium butyrate, 
H3Ac was increased at the promoter regions in both cell lines. H3K4me2 was higher at 
the coding and promoter regions of SW620. 
Considering that increased DNA methylation has been detected in the WNT5A 
Promoter A and B genomic regions in different cancer types, it would be expected that 
histone modifications will be associated with these changes and the silencing of Promoter 
B in the SaOS-2 cell line. The goals of this study are to determine if lack of Promoter B 
expression and increased DNA methylation at specific sequence regions and if specific 
modified histones are more enriched at Promoter A or B.  To accomplish these goals the 
following specific aims were completed:  
1. Determined the level of the WNT5A Promoter A and Promoter B transcripts in 
human osteosarcoma primary tumor tissue and U20S cell line.  
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2. Determined the DNA methylation profiles in WNT5A intron 1 CpG islands of the 
osteosarcoma cell line U20S.  
3. Compared the histone modifications in WNT5A intron 1 at select CpG islands of 
the osteosarcoma cell lines SaOS-2 and U20S.  
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CHAPTER II 
MATERIALS AND METHODS 
 
 
Cell Culture 
U20S (HTB-96) and SaOS-2 (HTB-85) osteosarcoma cells were obtained from 
the American Type Culture Collection (ATCC). The SaOS-2 cells were grown in 
McCoy’s 5a Modified medium containing 15% fetal bovine serum and 
penicillin/streptomycin (50 I.U. /50 µg per ml) (referred to as 15% Complete McCoy’s 
5a). The U20S cells were grown in 10% fetal bovine serum and penicillin/streptomycin 
(50 I.U. /50 µg per ml) (referred to as 10% Complete McCoy’s 5a). The U20S and SaOS-
2 cells were grown at 37°C in a 5% CO2 humidified cell culture incubator.  
Quantitative Real Time-PCR (qRT)-PCR 
RNA Isolation 
The medium was removed from the U20S cells grown in 100 mm plates. The 
cells were washed with cold 1x Phosphate Buffered Saline (PBS) and 5 ml of cold 1x 
PBS was added to the plates. The cells were scraped from the plates and transferred to a 
15 ml Falcon tube. The cells were centrifuged for 5 minutes at the #4 setting in a clinical 
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centrifuge and the supernatant was removed. RNA was isolated from the cell pellet using 
the SV Total RNA Isolation System (Promega, Z3105). 175 µl of RNA Lysis Buffer was 
added to the pelleted cells. The cell lysate was sheared using a 20-gauge needle, 4-5 
times to shear the genomic DNA. 350 µl of RNA Dilution Buffer was added. The sample 
was mixed and heated at 70 °C for three minutes. The sample was centrifuged for 10 
minutes at 14,000 rpm and the cleared lysate was transferred to a new microcentrifuge 
tube. 200 µl of 95% ethanol was added to the cleared lysate and mixed. The sample 
mixture was added to a Promega RNA isolation column and spun at top speed in a 
microcentrifuge for 1 minute. The column was washed with 600 µl RNA Wash Solution. 
The column was centrifuged for 1 minute. 50 µl of DNase incubation mix (containing 40 
µl of Yellow Core Buffer, 5 µl 0.9M MnCl2 and 5 µl of DNase I enzyme) was applied to 
the membrane of the column and incubated for 15 minutes at room temperature. After 
incubation, 200 µl of DNase Stop Solution was applied to the column and the column 
was centrifuged for 1 minute. The column was washed with 600 µl RNA Wash Solution 
and centrifuged for 1 minute. The sample was washed again with 250 µl of RNA Wash 
Solution and centrifuged for 2 minutes. The RNA was eluted from the column with 100 
µl of nuclease free water and centrifuged for 1 minute. The purity and quantity of the 
U20S RNA was determined by reading at 260 and 280 nm.  
5 µg of derived RNA from three primary human osteosarcoma tissues was 
obtained from Origene Technologies. Patient 1 RNA (CR559626) was isolated from a 
humerus parosteal osteosarcoma. Patient 2 RNA (CR562179) was isolated from 
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metastatic osteosarcoma. Patient 3 RNA (CR560767) was isolated from a recurrent 
osteosarcoma. 
cDNA Synthesis 
The U20S RNA and the RNA from the three primary osteosarcoma tumor tissues 
were converted into cDNA using the QuantiTect Reverse Transcription Kit (Qiagen, 
205313). A 1x reaction mixture consisted of 1µg of RNA, reverse transcriptase, reverse 
transcriptase buffer, primers, gDNA, and nuclease free water to give a final 20 µl 
reaction. The reverse transcriptase sample mixture was incubated for 5 minutes at 42 °C 
and then incubated at 95 °C for 3 minutes.  
The resulting cDNA was then used in qRT-PCR reaction to quantify Promoter A 
and Promoter B transcripts. Each reaction was run in triplicate with three target primer-
probes; Promoter A, Promoter B, and Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) (internal control) (Applied Biosystems HS99999905_m1) for each cDNA 
sample (U20S and three primary tumor tissues). Also, quantified Promoter A and 
Promoter B PCR products were run in triplicate to generate a standard curve. Standard 
curves were used to quantify the exact amount of Promoter A and Promoter B transcript 
levels. Using the line equation of the standard curves, the transcript levels of Promoter A 
and Promoter B can be calculated from the Ct values of the samples. The sequence of 
Promoter A and Promoter B primer-probes are given in Table 2. 
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Table 2. Taqman Primer-Probes for WNT5A Promoter A and Promoter B  
 
 Sequence 
(5’  3’) 
Length 
(base) 
Product 
Size 
(bp) 
Human Promoter A    
Forward TCGGGTGGCGACTTCCT 17  
77 Reverse CGCCCCCTCCCCCTCGCCATGAAG 24 
Probe TAACCTTATAATTCGGGTCCTCAAC 25 
Human Promoter B    
Forward CCTCTCGCCCATGGAATT 18  
71 Reverse CTTCAGGTAACCTTATAATTCGGG 24 
Probe CTGGCTCCACTTGTTGCTCGGCC 23 
(Hsu, 2011) 
Bisulfite Sequencing 
Genomic DNA Isolation 
 U20S cells were plated in 100 mm plates and grown for 2-3 days. The medium 
was removed and the cells were washed with 5 ml of 1x Hank’s. The cells were 
trypsinized and 3 ml of 10% Complete McCoy’s 5a medium added. The cells were 
transferred to a 15 ml Falcon tube and pelleted. The pelleted cells were resuspended in 3 
ml of 1x PBS and counted using a hemocytometer.  Aliquots representing 1x10
5
 were 
transferred to a microcentrifuge tube and pelleted. Genomic DNA was isolated from the 
cells following the directions of the Genomic DNA Isolation kit (Zymo research, D3004). 
To the pelleted cells, 10 µl of Zymobeads and 200 µl of Genomic Lysis Buffer were 
added and mixed. The sample stood at room temperature for 2 minutes and was 
centrifuged at 5,000 rpm for 1 minute. An additional 250 µl of Genomic Lysis Buffer was 
added to the sample and mixed. The sample was centrifuged for 1 minute at 5,000 rpm. 
 
20 
 
The sample was resuspended in 500 µl of gDNA Wash Buffer and centrifuged for 1 
minute at 5,000 rpm. Additionally, 500 µl of gDNA Wash Buffer was added to resuspend 
the sample pellet. The sample was centrifuged for 1 minute at 5,000 rpm. After the 
washes, 35 µl of Elution Buffer was added to the sample. The sample pellet was vortexed 
to break up the pellet and then incubated at 65°C for 5 minutes. The sample was vortexed 
briefly and centrifuged at maximum speed for 1 minute. The supernatant containing the 
genomic DNA was collected. The U20S genomic DNA quantity and purity was 
determined by reading an aliquot at 260 to 280 nm.  
Bisulfite Conversion 
 The U20S genomic DNA was bisulfite converted using the EZ DNA Methylation-
Direct Kit (Zymo Research, D5020). 500- 550 µg of genomic DNA was added to 5 µl of 
Dilution Buffer and adjusted to 50 µl using nuclease free water. The DNA mixture was 
incubated at 37°C for 15 minutes and the 100 µl of CT Conversion Reagent was added to 
the DNA sample mix. The sample mix incubated in the dark for 12-16 hours at 50°C. The 
sample mix was incubated on ice for 10 minutes. On a Zymo-Spin™ IC Column, 400 µl 
of Binding buffer and sample was loaded. The buffer and sample mix were mixed and 
centrifuged at maximum speed for 30 seconds. The column was washed with 100 µl 
Wash Buffer and centrifuge at maximum speed for 30 seconds. After centrifugation, 200 
µl of Desulphonation Buffer was added to the column and incubated at room temperature 
for 20 minutes. The column mix was centrifuged at maximum speed for 30 seconds. The 
column was washed twice with 200 µl of Wash Buffer and centrifuged at maximum 
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speed for 30 seconds. In a new microcentrifuge tube, the bisulfite converted DNA was 
eluted using 10 µl of Elution Buffer. The bisulfite converted DNA was read at 260 nm to 
280 nm to determine purity and quantity.  
PCR Amplification and Subcloning 
 1 µl of bisulfite converted DNA was used in PCR amplification using the 
previously designed WNT5A CpG Island primers specific for converted DNA of each of 
the six regions (Vaidya, 2013). The PCR amplification used the ZymoTaq DNA 
polymerase (Zymoresearch, E2001) at the appropriate amplification conditions listed in 
Table 3. The PCR product was verified by running 10 µl of the PCR products on a 2% 
agarose gel with 100 base pair marker and visualized through UV transillumination. 
Verified PCR products were extracted and purified using the QIAquick Gel 
Extraction Kit (Qiagen, 28704).  The remaining 40 µl of PCR product were run on a 2% 
low melt agarose gel using 100 base pair marker and visualized through UV 
transillumination. The correct DNA band was excised from the agarose gel and placed in 
a microcentrifuge tube. The gel slice was weighed and 3 volumes of QG Buffer was 
added to the gel slice. The gel slice was incubated at 50°C for 10 minutes or until the gel 
was dissolved. A gel volume of isopropanol was added to the dissolved gel and mixed. 
The sample was applied to a QIAquick Spin Column and centrifuged for 1 minute. The 
column was washed with 750 µl of PE Buffer and centrifuged for 1 minute. The purified 
DNA was eluted from the column using 50 µl of Elution Buffer. The purified DNA was 
read at 260 and 280 nm for purity and quantity.  
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The purified DNA was cloned in the pGEM-T vector using the pGEM-T Easy 
Vector System (Promega, A1360).  The amount of purified DNA cloned into the vector 
was calculated based on base pair size of the insert using the formula provided. The 
ligation reaction was incubated overnight at 4°C. After ligation, 5 µl of the ligation 
reaction was transformed into 100 µl of competent DH5α E.coli. The competent cells 
plus ligation mix was incubated on ice for 20 minutes. The cells were heat shocked for 
45-50 seconds at 42°C. The tubes were returned to ice and 500 µl of room temperature 
SOC medium was added. The cells were incubated with shaking for 1 hour at 37°C.  200 
µl of the cells were plated onto Luria Broth (LB) – Ampicillin (AMP) plates with 40 µl 
X- gal (5-bromo-4-chloro-3-indolyl-beta-D-galacto-pyranoside) (40 mg/ml) and 
incubated overnight at 37°C.  
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Table 3. Bisulfite Sequencing PCR Primers, Anneal Temperature and Product Size 
  
Primer Name Sequence (5’-3’) Anneal 
Temp 
Size 
(bp) 
W5AR1F AGTAATAGGATAATGATTTAATTTAATAAA 45°C  393 
W5AR1R CAAAATACCTAAACTCACCCAATA 
W5AR2F AGTTTTTAGATAGATTTTGTTAGGGGAGT 45°C 255 
W5AR2R CATAATACTAACCCCTTAAACACC 
W5APrBR2HF GTTTAAGAGTTTTTTGTTTTTTTT  335 
W5APrBR2HR AAATACCAACCCTATATCCAACTAAC 
W5aR3F#2 GAGGATTTTTGTTTGGTTTTTTTATT 55°C  441 
W5AR3R AAACTAAATATTTTCCAACACTTTC 
W5AR4F GTTTTGGGAATTGGTGGATTT 45°C  329 
W5AR4R AACCCAAACTACAAAATCAACTCTC 
W5AR4F3H2 GAATTTGTTATTAATTTTTTTGTTGTTTG 58°C  226 
W5AR4R3H2 TACAAAATCAACTCTCCCCAAAA 
W5APrBR5nF AGGGTTGTTTAGGTTTTTTTTGTTT 45°C  578 
W5APrBR5nR AACTCCAATTTCCCTTAATCCTAAT 
W5AR6F  TTTTTTTTAGTTTGGTTGAAGAA 55°C  393 
W5AR6R  CCTAAATAATTCACTCAAAAACCC 
W5AR6H2F5 AATTAATTTTGGTTTTATTTGTTGTT 55°C  96 
W5AR6H2R5 TCAATCCCTCCTAAATAATTCACTC 
(Vaidya, 2013) 
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Plasmid Screening, Plasmid Purification and Sequencing 
White colonies grown on a LB-AMP master plate and cultured overnight at 37°C 
in 3 ml of LB containing 100 µg/ml ampicillin were picked. The overnight culture was 
used to conduct a quick miniprep analysis method using a boiling water bath (Riggs and 
McLachlan, 1986). 1 ml of the cultured broth was centrifuged for 1 minute at maximum 
speed. The supernatant was removed and the bacteria pellet resuspended in 200 µl of 
Lysis Buffer/Lysozyme mixture (8% sucrose, 0.5% triton X-100, 50 mM EDTA, 10 mM 
Tris-HCl (pH 8.0) with 750 µg lysozyme per ml). The samples were boiled for 40 
seconds then immediately placed on ice. The sample was centrifuged for 10 minutes at 
maximum speed and placed on ice. 10 µl of the supernatant was removed and run on a 
2% agarose gel with Lambda phage Hind III marker. The gel was visualized through UV 
transillumination and photographed using a Bio Rad Molecular Imager Gel Doc XR 
system. Samples showing a supercoiled plasmid band running slower than the plasmid 
band in the “without insert” blue control sample were further purified for sequencing 
using the Qiagen QIAprep Miniprep kit (Qiagen, 27106).  The remaining 2 ml of the 
liquid culture was centrifuged for 5 minutes and the supernatant removed. The bacteria 
pellet was resuspended in 250 µl of P1 Buffer. Next, 250 µl of P2 Buffer was added and 
mixed thoroughly. 350 µl of N3 Buffer was added to the sample and the sample was 
mixed thoroughly. The sample was centrifuged for 10 minutes at 13,000 rpm. 
Supernatant from centrifugation was applied to a QIAprep Spin Column. The column 
was centrifuged for 1 minute. The column was washed with 750 µl of PE Buffer and 
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centrifuged for 1 minute. The purified plasmids were eluted by adding 50 µl of Elution 
Buffer to the column and letting it sit for 1 minute before centrifuging for 1 minute. 10 µl 
of the purified plasmids of at least 100 ng/ul were sent to Eurofin MWG Operon 
sequencing facility for sequencing. The plasmid DNA concentration was determined by 
reading the OD at 260 to 280 nm. Plasmid samples that were too dilute were concentrated 
in a speed vac concentrator.  
DNA Sequencing Analysis 
 DNA Sequencing was performed by  Eurofin MWG Operon. Using the 
MacVector Sequence (Version 12.0.3) analysis software, each sequence was aligned to a 
computer generates bisulfite converted sequence of that region assuming all C’s are 
methylated. As such all C’s in the CpG island remain a C and all other C’s were 
converted to T’s. Once aligned, an unmethylated experimental CpG would be converted 
to a T and would not align the methylated CpG, which remains a C.  A methylated 
experimental CpG would remain a C and would align the methylated CpG.  
 
Chromatin Immunoprecipitation (ChIP) Assay  
Cell Fixation 
A ChIP assay was performed following the instructions of the ChIP –IT Express 
kit (Active Motif, 53008) to study the histone modifications in U20S and SaOS-2 cell 
lines. The U20S and SaOS-2 cells were grown to 70% confluency using nine 100 mm 
plates for each cell line. The medium was poured off the plates. The cells were fixed by 
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adding 6.5 ml of 37% Formaldehyde Fixation Solution per plate and shaking for 10 
minutes at room temperature. The Fixation Solution was poured off and the plates were 
washed with 3.3 ml cold 1x PBS. The PBS was poured off and 3.3 ml Glycine Stop 
Solution was added to the plates and incubated at room temperature with shaking for 5 
minutes. The Glycine Stop solution was removed and the cells were washed with 3.3 ml 
cold 1x PBS. 1.5 ml of Cell Scraping Solution (containing 120 µl of 
phenylmethanesulfonyl fluoride (PMSF) ( 100mM) was added to each plate and the cells 
were scraped then transferred to a 15 ml Falcon tube. The cells were pelleted by 
centrifuging at 4°C for 10 minutes at 2,500 rpm. The supernatant was removed and 
chromatin shearing was immediately conducted. We determined that the fixed cells could 
not be frozen before chromatin shearing.  
 
Chromatin Shearing 
 The pelleted cells were resuspended in 3 ml of ice cold Lysis Buffer 
[supplemented with 15 µl of Protease Inhibitor Cocktail (PIC) and 15 µl of PMSF 
(100mM)] and incubated for 30 minutes on ice. The cells were transferred to an ice cold 
Dounce homogenizer and dounced on ice with about 30 strokes to help with nuclei 
release. Looking at dounced cells under a phase contrast microscope was helpful to 
ensuring nuclei release. The dounced cells were transferred to a 1.5 microcentrifuge tubes 
and centrifuged for 10 minutes at 5,000 rpm at 4°C to pellet nuclei. The supernatant was 
removed and the nuclei resuspended in 300 µl of Shearing Buffer [supplemented with 5 
µl PIC and 5 µl of PMSF (100 mM)]. The samples were placed on ice and different 
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sonication conditions were tested. The best sonication conditions for U20S was 10 pulses 
of 20 seconds on and 40 Seconds off between level 1 and 2 on a 60 Sonic Dismembrator. 
The best sonication conditions for SaOS-2 was 12 pulses of 20 seconds on and 40 
seconds off between level 1-2 on a 60 Sonic Dismembrator (Fisher Scientific). The 
sheared chromatin was centrifuged for 10 minutes at 14,000 rpm at 4°C. The supernatant 
containing the sheared chromatin was transferred to new microcentrifuge tubes. 50 µl 
aliquots from each chromatin sample were put into new microcentrifuge tubes for 
analysis of DNA size.  
 
DNA Clean Up and Shearing Efficiency Test 
To the 50 µl aliquots of each sample, 150 µl of deionized water and 10 µl of 5M 
NaCl were added. The samples were heated to 65°C in a thermocycler overnight to 
reverse cross link the fixed chromatin sample. 1 µl of RNase A (10 µg/µl) was added to 
each sample which were incubated at 37°C for 15 minutes. Next, 10 µl of Proteinase K 
(0.5 µg/µl) was added to each sample and incubated at 42°C for 90 minutes.  Then, 200 
µl of 1:1 phenol/chloroform TE saturated pH 8.0 was added to the samples, mixed and 
centrifuged for 5 minutes at maximum speed. The aqueous phase was transferred to a 
new microcentrifuge tube. To the aqueous phase, 20 µl of 3M sodium acetate, pH5.2 and 
500 µl 100% ethanol was added and mixed completely. The samples were placed at -
80°C for 1 hour. The samples were centrifuged at maximum speed for 10 minutes at 4°C. 
The supernatant was removed and without disturbing the pellet, 500 µl of ice cold ethanol 
was added. The samples were centrifuged at maximum speed for 5 minutes at 4°C. The 
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supernatant was removed and the pellet air dried. The dried pellet was resuspended in 30 
µl of sterile water. The concentration and purity of the DNA was measured at 260 and 
280 nm. On a 1% agarose gel, 5 µl of the DNA samples were run with 100 base pair 
marker, and visualized by UV transillumination, and photographed. Sheared chromatin 
showing DNA between 200-1500 base pair were used for immunoprecipitation.  
 
Immunoprecipitation 
The sheared chromatin with the correct DNA size spread was used in 
immunoprecipitation. In a new microcentrifuge tube, 10 µl of this sheared chromatin was 
extracted as “Input DNA” to be used later in PCR analysis. Using the provided 
siliconized 1.7 ml microcentrifuge tubes, a 100 µl reaction mix was made using 25 µl 
Protein G Magnetic Beads, 10 µl ChIP Buffer 1, 25 µg of sheared chromatin, 1 µl PIC, 
water, and 1-3 µg of antibody. (Antibody was added last to the reaction.) Antibodies for 
the different samples were RNA Polymerase II (Active Motif 39097), IgG and 
H3K27me3 (AbCam ab6002). A bridging antibody was used with the RNA polymerase 
II, mouse monoclonal anti-H3K27me3 and IgG (Active Motif 53017). The samples were 
incubated on a rotator overnight at 4°C. After incubation, the samples were centrifuged 
briefly and placed on the magnetic stand to pellet the beads to one side of the tube. The 
supernatant was removed and 800 µl of ChIP Buffer 1 was used to resuspend the beads.  
The beads were pelleted again using the magnetic stand. Then, 800 µl of the ChIP Buffer 
2 was added twice to resuspend the pelleted beads. The Wash Buffer was removed 
completely. 
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Elution of Chromatin, Reverse Cross Linking and Proteinase K Treatment 
 The beads were resuspended in 50 µl of Elution Buffer AM2. The beads and 
buffer were incubated at room temperature for 15 minutes on a end to end rotator at 4°C. 
Tubes were briefly centrifuged and 50 µl of Reverse Cross Linking Buffer was added. 
The samples were mixed by pipetting and the tubes were placed on the magnetic stand. 
The supernatant containing the chromatin was transferred to a thermocycler tube. The 
“Input DNA” was processed by adding 88 µl of ChIP Buffer 2 and 2 µl of 5M NaCl to 
the DNA. The ChIP samples and “Input DNA” was incubated at 95°C for 15 minutes in a 
thermocycler. The tubes were briefly centrifuged and 2 µl of Proteinase K (0.5 µg/µl) 
was added to each sample. The samples were mixed and incubated at 37°C for 1 hour. 
The Proteinase K Stop Solution was placed at room temperature during this incubation. 
After incubation, 2 µl of Proteinase K Stop Solution was added to the samples. The 
samples were centrifuged to collect the liquid. 
 
Chromatin IP DNA Purification  
  The chromatin was purified using the Active Motif Chromatin IP DNA 
Purification Kit (Active Motif, 58002). For every volume of DNA sample, 5 volumes of 
DNA Purification Binding Buffer were added along with 5 µl of 3M sodium acetate. The 
samples were mixed and color of buffer was a bright yellow (If the color is bright orange 
or violet, additional 3M sodium acetate at 5 µl should be added until the color is yellow). 
The samples were applied to the DNA Purification columns and centrifuged at 14,000 
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rpm for 1 minute. To the column, 750 µl of Wash Buffer was added and centrifuged for 
14,000 rpm for 1 minute. The uncapped tubes were centrifuged at 14,000 rpm for 2 
minutes to remove residual Wash Buffer. The purified DNA was eluted by adding 50 µl 
of Elution Buffer to the column and centrifuging for 1 minute.   
 
Primer Design 
Due to the GC rich sequences of the WNT5A regions of interest, primers were 
designed visually. The primers were designed to be 16-25 base pairs, CG at the 3’ end, 
melting temperatures within 3°C of each other and no more than 150 base pair amplicon 
length. The selected primers were analyzed for self-complementary and secondary 
structures using the Thermo Scientific Multiple Primer Analyzer 
(http://www.thermoscientificbio.com/webtools/multipleprimer/). The sequences of the 
ChIP primers are shown in Table 4. The primers for the Promoter B region flank 
Promoter B transcription start site, Exon 1β. The primers for Promoter A flank Promoter 
A transcription start site and the Exon1.  The primers for Regions 3, 4 and 5 were outside 
of the targeted outside of the CpG island. 
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Table 4. ChIP qRT-PCR Primers  
 
Primer name Sequence(5’-3’) 
Promoter B   
2WntChipPrBExF2b CCACCCCGCCTCCTTGG 
2WntChipPrBExR2b GCCACCCTCCGTCCTCTCC 
WPrBChIPF2a GCTCCACTCGCCTCCGTG 
WPrBChIPR2a GCCTCCTTCCTGCTCGCTC 
Promoter A   
2WntProAChIPEx1F1 GCCTCTCCGTGGAACAGTTGC 
2WntProAChIPEx1R2 CTGGGATGCGCCCAGG 
WntProAEx1F4 CGCCAGTGCCCGCTTCAG 
WntProAEx1R4 CAGCCGAGGAATCCGAGC 
Regions   
ChipR3AFor TGGGTCAAATGGGCTTCTTCC 
ChipR3ARev TCTGGGAGTGAAACGATGAGGG 
ChipR4AFor GAGATGCGACTCGTGAGGCTC 
ChipR4ARev GCTCCAGGGTAGAGGTAGGCAG 
ChipR5AFor GGCGGCTCACGGAGAAAAAC 
ChipR5ARev AAAAGGGGCAGAGGGGACC 
 
 
Real Time PCR and Enrichment 
 ChIP enrichment was determined by qRT-PCR using SYBR-Green reagents. 
Each qRT-PCR set included a dilution series of the “Input DNA” to generate a standard 
curve for each primer set.  The dilution series of the “Input DNA” consisted of three 10-
fold dilutions of standard or 1, 1:10 and 1:100.  The ChIP anti RNA polymerase II, IgG,  
anti- H3K27me3, anti-H3K9me3 and anti-H3K4me3 samples have different 
amplification profiles and were run in triplicate for each primer set. GAPDH was also 
used as a standard control for our ChIP samples and was run in triplicate with each 
primer set. GAPDH is a highly expressed gene. Using the linear regression plot of the 
“Input DNA”, the Ct values of the different samples can be plotted and the enrichment 
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can then be calculated. The fold enrichment was determined according to the method for 
qRT-PCR described in ChIP-IT Express. The DNA quantity of the ChIP for a given 
primer and the negative control (IgG) were solved using the equation, Y= M (log X) + B. 
Where X is the DNA quantity, Y is the cycle number for that sample, M is the slope of 
the standard curve, and B is the cycle number where X=1. The fold enrichment was 
calculated by the “ChIP DNA quantity” divided by “IgG DNA quantity”.  
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CHAPTER III 
RESULTS 
  
 
WNT5A Promoter A and Promoter B Transcripts in Human Osteosarcoma Primary 
Tumor Tissue and U20S Cell Line 
Higher Levels of Promoter A than Promoter B transcripts in U20S osteosarcoma cells 
 Previous results in the lab showed that WNT5A Promoter A transcripts are higher 
in comparison to Promoter B transcripts in the SaOS-2 osteosarcoma cell line, whereas in 
normal osteoblasts, Promoter B transcripts were higher than Promoter A transcripts (Hsu, 
2012; Table 5).  We wanted to determine if this pattern of WNT5A expression is specific 
to SaOS-2 or more general to osteosarcoma cells. RNA was isolated from the U20S 
osteosarcoma cell line and converted into cDNA. qRT-PCR was conducted using 
previously designed Taqman primer-probes that distinguish between Promoter A and 
Promoter B transcripts (Hsu, 2012).  A five point standard curve was generated using 
purified PCR products with known molecule numbers for each dilution (Figure 3A).  The 
standard curve line equation was used to calculate the copy numbers of the Promoter A 
and Promoter B transcripts per µg RNA using the generated Ct values of the samples 
(Figure 3B).  This was repeated three times.  
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Figure 3. Promoter A and Promoter B Transcript Levels in U20S Osteosarcoma  
Cells. Total RNA was isolated from U20S, converted to cDNA, and used for qRT-PCR. 
A. Standard curves of Promoter A and Promoter B PCR products at known copy 
numbers. The derived linear equation for each line is shown. B. One example of 
quantification of Promoter A and B transcripts, expressed per µg RNA. The Ct values 
from qRT-PCR are used to solve for X in the linear equations of the standard curves. 
Bars are standard error calculated from three technical replicas. 
 
 
 There are higher numbers of Promoter A transcripts in comparison to Promoter B 
transcripts in the U20S cell line. From three independent determinations the average  
Promoter A to Promoter B transcript ratio was 11.9 (Table 5). These results confirm that 
Promoter A transcripts are higher than Promoter B transcripts in another osteosarcoma 
cell line (U20S) in addition to SaOS-2 
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.   Table 5.Transcript Numbers and Promoter A/Promoter B Ratio.  
 
Sample Transcripts per µg RNA
1
 A/B Ratio 
Normal osteoblast A – 5.3 x 10
6
 ± 0.8 x 10
6
 
B – 5.9 x 10
7
 ± 1.6 x 10
6
 
0.09 ± 0.02
2
 
Osteosarcoma cell line   
SaOS-2 A – 6.8 x 10
6
 ± 0.5 x 10
6
 
B – 3.3 x 10
4
 ± 0.7 x 10
4
 
224.5 ± 65.2
2
 
U20S A – 9.7 x 10
5
 ± 1.5 x 10
5
 
B – 1.1 x 10
5
 ± 0.7 x 10
4
 
11.9 ± 4.1 
Osteosarcoma tumor 
tissue 
  
Patient 1 A – 5.3 x 10
4
 ± 0.2 x 10
4
 
B – 6.3 x 10
3
 ± 1.2 x 10
3
 
9.2 ± 3.5 
Patient 2 A – 1.2 x 10
5
 ± 0.03 x 10
5
 
B – 1.6 x 10
4
 ± 0.05 x 10
4
 
7.5 ± 0.7 
Patient 3 A – 7.9 x 10
3
 ± 0.1 x 10
3
 
B – 1.1 x 10
2
 ± 0.2 x 10
2
 
78.5 ± 27.8 
1
 ±standard error, n=3. 
2
Hsu, 2012. The p value for Promoter A to Promoter 
B transcripts for all samples was P < 0.005.   
 
 
Osteosarcoma primary tumor tissues have reduced levels of Promoter B transcripts 
 Next we wanted to determine if the higher levels of Promoter A transcripts in 
comparison to Promoter B transcripts measured in both U20S and SaOS-2 was a 
characteristic of primary osteosarcoma tissue. The RNA from three different 
osteosarcoma patients was purchased. Patient 1 RNA was isolated from a humerus 
parosteal osteosarcoma. Patient 2 RNA was isolated from metastatic osteosarcoma. 
Patient 3 RNA was isolated from a recurrent osteosarcoma.  Promoter A and Promoter B 
transcript copy numbers were quantified in these RNA samples by qRT-PCR using a 
standard curve, as described.  
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The results of one of the human primary patient tissue assays are shown in Figure 
4. All three osteosarcoma tissue samples had higher Promoter A transcript levels in 
comparison to Promoter B. The A to B ratio for the three patient tissue samples are found 
in Table 5. Patient 1 and Patient 2 were more similar having 9.2x and 7.5x, respectively, 
more Promoter A than Promoter B transcripts, whereas Patient 3 had 78.5x more 
Promoter A than Promoter B transcripts. These results indicate that a higher level of 
Promoter A than Promoter B transcripts is a characteristic of osteosarcoma cancers.  
Overall, transcript numbers per µg RNA in patient tissues for both Promoter A 
and Promoter B were lower than determined for SaOS-2 and U20S by approximately 10-
fold or more (Table 5).  
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Figure 4. Higher Numbers of WNT5A Promoter A Transcripts in relation to 
Promoter B Transcripts in Patient Osteosarcoma Tumor Tissues. RNA was 
purchased and converted to cDNA. Promoter A and Promoter B transcripts were 
quantified by qRT-PCR using a standard curve. Standard error calculated from three 
technical replicas. WNT5A transcript copy numbers are expressed per µg of RNA.  
 
 
Increased DNA Methylation of CpG Islands Associated with Promoter B in 
Osteosarcoma Cell Line U20S 
 It was previously shown in the lab that the decrease in Promoter B transcripts in 
SaOS-2 cells is associated with DNA methylation of particular sequences (Vaidya, 2013). 
We wanted to determine if DNA methylation was also involved in the decrease in 
Promoter B activity in U20S cells and how the pattern of DNA methylation compares to 
SaOS-2 cells. This is important as it may reveal sites of DNA methylation that are more 
prone to epigenetic modulation in osteosarcoma cancers. The methylation status of the 
six CpG islands shown in Figure 5A was analyzed through bisulfite sequencing. This was 
accomplished by using previously designed bisulfite sequencing specific primers that 
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amplify their respective CpG island in bisulfite modified DNA (Table 3; Vaidya, 2013). 
After bisulfite modification and amplification, the PCR products were subcloned and 
sequenced. The results of bisulfite sequencing are shown in Figure 5B.  
 The 27 CpGs of Region 1 CpG island were completely unmethylated in the five 
analyzed clones.  Region 2 CpG island has 39 CpGs, but only the first 16 CpGs were able 
to be cloned in the six clones analyzed. The first 16 CpGs were unmethylated. Region 3 
CpG island of 24 CpGs was found to be completely methylated in four of the six clones 
analyzed. The other two clones had only one unmethylated CpG out of the 24 CpGs.  
Region 4 CpG island has 27 CpGs but only CpGs 6-25 were able to be cloned. The CpGs 
7-25 of Region 4 were shown to be methylated, but CpG 6 was unmethylated of the three 
clones analyzed. The CpG island Region 5 has 27 CpG’s but only the first 22 CpGs were 
cloned. These 22 CpGs of Region 5 were methylated with the exception of CpG’s 18 and 
20, which were unmethylated of the four clones analyzed.  
CpG Region 6 is associated with the Promoter B start of transcription and Exon 
1β. It has 26 CpGs. Only two full length Region 6 clones were obtained and these were 
all unmethylated. We used a different primer set that amplified a region that includes 
only four of the CpG’s in Region 6. Six of the nine clones obtained were found to be 
completely unmethylated, two were completely methylated, and one has three of the four 
CpG’s methylated. Overall, these results indicate that U20S have some sequences 
associated with Promoter B that are methylated, which may contribute to the reduction in 
Promoter B transcript levels. 
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Figure 5. CpG Island Regions 1-6 and Methylation Status in U20S Osteosarcoma 
Cells. A. Location of CpG islands in WNT5A intron 1. R1-R6 are the CpG island regions 
with the number of CpG’s in the sequence given in parentheses The numbers indicate 
relative base pair within the intron sequence with the first base pair of the intron as 
number 1. B. Results of bisulfite sequencing in U20S. Each circle represents a CpG 
within that particular CpG island region. Numbers correspond to the CpG relative 
location within the region. Closed circle = methylated CpG; open circle = unmethylated 
CpG. Each row is an individual sequenced clone.  
 
 
Reduction in H3K4me3 Enrichment in Promoter B Region 6 
 Increased methylation was detected in Regions 3, 4, and 5 of U20S. However, 
Region 6, associated with the Promoter B start of transcription, was less methylated. 
Thus, the reduction in Promoter B activity in U20S may potentially be due to histone 
modifications and not primarily to DNA methylation. We used chromatin 
immunoprecipitation (ChIP) assay to examine Promoter A, Promoter B, and Regions 3, 4, 
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and 5 for enrichment of specific histone modifications. These included H3K27me3, 
H3K4me3, and H3K9me3. The histones H3K27me3 and H3K9me3 are repressive 
histone marks. H3K4me3 is an activating histone mark. As controls, we performed ChIP 
using anti-RNA polymerase II, which should be present in active promoters, and as a 
negative control that should not “pull-down” anything specific chromatin, anti IgG was 
performed in the ChIP assays. The locations of the primers used in ChIP are shown in 
Figure 6A. A GAPDH primer was also run with all ChIP assays as a highly expressed 
gene.  
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Figure 6. Chromatin Immunoprecipitation (ChIP) Assay of U20S Cells at the 
WNT5A Promoter A and Promoter B Genomic Region. A. The location of the ChIP 
primers for Promoter A, Promoter B and the Regions 3, 4, and 5.  Fold enrichment for 
Promoter A and B probes of B. RNA polymerase II, C. H3K27me3, D. H3K9me3, E. 
H3K4me3. F. Fold enrichment of H3K4me3, H3K9me3 and H3K27me3 at Regions 3, 4, 
5, G. Fold Enrichment for GAPDH. 
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 RNA polymerase II was enriched on both Promoter A and Promoter B (Figure 
6B). In fact, enrichment was greater using Promoter B primer B1 but it is likely that this 
is not significant, considering primer B2 overlaps B1. Also, greater enrichment would not 
be expected considering the lower levels of Promoter B activity in U20S. In comparison, 
the highly expressed GAPDH had much higher levels of RNA polymerase II enrichment 
than either Promoter A or B (Figure 6G; Table 6). This would be expected.  
 The repressive histone marks, H3K27me3 and H3K9me3, appeared equally 
enriched at both Promoters A and Promoter B (Figure 6C and D). The level of 
enrichment is similar to what is observed in GAPDH (Figure 6G; Table 6), therefore this 
likely represents levels that are unrelated to transcriptional inactivation.  
In contrast, the active histone mark, H3K4me3, had higher levels of enrichment 
for Promoter A probes in comparison to the Promoter B probes (Figure 6E; Table 6). The 
GAPDH gene had high levels for H3K4me3 enrichment, which would be expected for a 
highly expressed gene (Figure 6G). These results suggest that H3K4me3 is reduced at the 
Promoter B Region 6.  
 The three histone marks, H3K27me3, H3K9me3 and H3K4me3 were examined in 
Regions 3, 4 and 5 (Figure 6F). Regions 3 and 4 had higher levels of enrichment of 
H3K27me3, even in comparison to GAPDH (Table 6). Region 5 had H3K27me3 
enrichment levels similar to GAPDH. In relation to Promoter A, Promoter B and 
GAPDH, Regions 3, 4 and 5 had no enrichment of H3K9me3 (Table 6). For H3K4me3, 
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Regions 3, 4 and 5 had lower levels of enrichment more similar to Promoter B (Figure 
6F; Table 6).  
 
Table 6. Chromatin Immunoprecipitation (ChIP) Fold Enrichment Values of U20S 
and SaOS-2. 
 
 
 
 In SaOS-2, we used ChIP to examine Promoter A and Promoter B for the 
repressive histone modification, H3K27me3 (Figure 7). The controls, anti-RNA 
polymerase II and IgG were also used in SaOS-2. GAPDH was run with the ChIP as a 
highly expressed gene (Figure 7D). The results of SaOS-2 have a similar pattern to the 
U20S results above except their enrichment levels are much lower than U20S. In SaOS-2, 
there were similar level of enrichment for RNA polymerase II for Promoter A and 
Promoter B (Figure 7B).  For H3K27me3, the Promoter B probes primer B1 and B2 
showed some, but low enrichment, whereas the Promoter A probes show essentially no 
enrichment (Figure 7C). Enrichment of H3K27me3 for Promoter A would not be 
expected due to the higher activity level of Promoter A in SaOS-2. A higher enrichment 
U20S 
 A1 A3 B1 B2 Reg 3 Reg 4 Reg 5 GAPDH 
RNA 
polymerase 
II 
37.22 49.73 135.24 43.71 _ _ _ 713.93 
H3K4me3 104.45 219.56 24.96 4.01 18.61 9.8 6.6 1402.82 
H3K9me3 9.55 26.902 22.65 3.32 31.72 18.29 8.13 26.89 
H3K27me3 7.91 13.39 20.28 14.9 57.85 44 15.42 19 
SaOS-2 
 A1 A3 B1 B2 GAPDH 
RNA 
polymerase II  
5.32 5.74 2.97 4.17 2624.25 
H3K27me3 1.48 0.25 2.52 1.46 10.83 
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level of H3K27me3 on Promoter B Region 6 might be expected. GAPDH had very high 
levels of RNA polymerase II enrichment and some enrichment for H3K27me3 (Figure 
7D; Table 6). The results suggest there was no enrichment for H3K27me3 at either 
Promoters A or B.  
 It is not clear why enrichment levels were overall so low for the WNT5A genomic 
region in SaOS-2, considering the values for GAPDH were similar to U20S. A possible 
answer to the low enrichment values for SaOS-2 could be the DNA methylation and 
steric hindrance to antibody binding.  Histone tails serve as docking sites for transcription 
factors or other modifying enzymes. The binding of these proteins could block access of 
the antibody for a histone modification (Collas, 2010). Also the tight packaging of 
histones could block an antibody from binding to a targeted histone modification 
(Kimura, 2013).  
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Figure 7. Chromatin Immunoprecipitation (ChIP) Assay of SaOS-2 Cells at the 
WNT5A Promoter A and Promoter B Genomic Region. A. The location of the primer 
probes for Promoter A and Promoter B.  Fold enrichment for Promoter A and B probes as 
B. RNA polymerase II, C. H3K27me3, D. GAPDH. 
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CHAPTER IV 
 
DISCUSSION 
 
 
Summary of Major Findings 
 In this study, the WNT5A Promoter A and Promoter B transcript levels were 
examined in the U20S osteosarcoma cell line and patient osteosarcoma tumor tissue 
samples. Our results suggest that a decrease in Promoter B transcripts in relation to 
Promoter A transcripts is a feature of osteosarcoma cancers. The DNA methylation status 
of six CpG islands that may be associated with Promoter B transcription was determined. 
The results showed that Regions 1 and 2 were completely unmethylated. Regions 3, 4, 
and 5 were highly methylated, whereas Region 6, which includes the transcription start 
site of Promoter B, was less methylated in comparison to SaOS-2 cells. The level of 
methylation was negatively correlated with Promoter B transcription. This results 
indicates that methylation of Region 6 may not be the underlying cause of the reduction 
in Promoter B transcript levels. Chromatin immunoprecipitation (ChIP) analysis suggests 
that the repressive histone marks, H3K9me3 and H3K27me3, are similar between the 
Promoter A and Promoter B regions. Significantly, Promoter A is more enriched in the 
active histone mark, H3K4me3 than Promoter B. These results indicate that histone 
modifications and DNA methylation are contributing to the reduction of Promoter B 
activity in U20S cells.  
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Decreased Promoter B Transcripts in Osteosarcoma Cell Lines and Primary 
Osteosarcoma Tissues 
 WNT5A is a key protein involved in maturation of osteoblasts and thus it is 
expected to be involved in osteosarcoma. WNT5A has been shown to be expressed in 
osteosarcomas. In SaOS-2 and U20S, it has been found that constitutively active WNT5A 
signaling increased MMP-13 activation and invadopodia formation that leads to cell 
invasion in these cancer cells (Enomoto et al., 2009). More recently, WNT5A has been 
shown to promote migration of human osteosarcoma cells through the 
phosphatidylinositol-3 kinase/Akt signaling pathway (Zhang et al 2014). These studies 
clearly support the conclusion that WNT5A has oncogenic activities in osteosarcoma 
cells. However, in these studies the focus was on the transcripts derived from Promoter A 
and its protein product.   
In our lab, the transcript levels from the WNT5A Promoters A and B were 
analyzed in osteoblasts and SaOS-2 osteosarcoma. In normal osteoblasts, Promoter B 
transcripts were higher in comparison to Promoter A transcripts (Hsu, 2012). The A to B 
transcript ratio was 0.09 ( ± 0.02) (Table 5).  These results suggest that in normal 
osteoblast Promoter B is more active. In contrast to osteoblasts, SaOS-2 osteosarcoma 
cells had Promoter A transcripts similar to or slightly higher than in osteoblast cells, 
whereas Promoter B transcripts were greatly reduced (Hsu, 2012). The ratio of A to B 
was 224.5 (±65.2) (Table 5). Hence, Promoter B transcript numbers were approximately 
2000 times higher in normal osteoblast cell than in SaOS-2 osteosarcoma cells.  
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Corresponding protein levels for Promoter A and Promoter B are not known. 
Differentiation between Promoter A and Promoter B protein isoforms requires antibodies 
specific to each isoform.  
In this study, we analyzed Promoter A and B transcript levels in U20S cells to 
determine if the decrease in Promoter B is a characteristic of osteosarcoma cell lines. The 
Promoter A transcripts were 9.7x10
5 
(per µg of RNA), which is lower than in normal 
osteoblasts and SaOS-2 cells. Promoter B transcripts were 1.1x10
5
 (per µg RNA), which 
were higher than Promoter B transcripts in SaOS-2 but lower than transcripts numbers in 
normal osteoblasts. The A to B ratio for U20S was 11.9 (±4.1) (Table 5). Promoter B 
transcripts in normal osteoblasts are about 500 times higher than in U20S cells. Overall, 
these results suggest that a reduction in Promoter B is common to osteosarcoma cell 
lines.  
 It was important to determine if the reduction in Promoter B transcript levels is 
common in primary osteosarcoma tumor tissue. RNA from three different patient tumor 
tissues were purchased and analyzed for WNT5A Promoter A and Promoter B 
transcripts. All three patient tumor tissue samples had lower levels of Promoter B in 
comparison to Promoter A transcripts. Patients 1 and 2 had an A to B ratio of 9.2 and 7.5, 
respectively. Patient 3 had an A to B ratio of 78.5. Patients 1 and 2 had an A to B ratio 
similar to the U20S cell line. Patient 3 had an A to B ratio more similar to SaOS-2 cell 
line.  
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The absolute levels of WNT5A promoter A and B transcripts per µg RNA in the 
primary tumor tissues is relatively low, in comparison to the cell lines. For example, 
patients 1 and 3 had only 5x10
4
 and 8x10
3
 transcripts per µg RNA of Promoter A 
transcripts, respectively (Table 5). Patient 2 had a higher level at 1x10
5
 per µg RNA but 
still less by nearly 10 fold as in U20S. The lower levels of transcripts per µg of RNA are 
likely due to the tumor tissue including other cell types.  
 It is of potential significance that Patient 2 RNA was isolated from a metastatic 
osteosarcoma and the levels of both Promoter A and B transcripts were higher in this 
sample. However, the A to B ratio was lowest of the three tissues. As previously 
discussed, high levels of WNT5A Promoter A isoforms can induce cellular characteristics 
of metastasis in osteosarcoma cells.  
Patient 1 had a humerus parosteal osteosarcoma and Patient 3 had a recurrent 
osteosarcoma. Both these patients had lower Promoter A and Promoter B transcripts than 
Patient 2.  Patient 2 had a metastatic osteosarcoma and had higher levels of Promoter A 
and Promoter B transcripts in comparison to the other patient tissues. Looking at the 
transcript numbers and types of cancers from each patient, there may be a decrease in 
Promoter B as the osteosarcoma cancer progresses.  
 Overall, results with, U20S, SaOS-2, patient tumor tissue and normal osteoblasts 
suggests that during cancer progression in osteosarcoma, Promoter B is being inactivated.  
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Aberrant DNA Methylation of WNT5A Intron 1 CpG Islands in U20S Osteosarcoma 
Cells 
 Previous bisulfite sequencing was conducted on WNT5A CpG islands located in 
intron 1 in osteoblast and SaOS-2 osteosarcoma cells in our lab. In osteoblast, all CpG 
island Regions 1 to 6 were completely unmethylated (Vaidya, 2013). In SaOS-2, Regions 
1 and 2 were completely unmethylated. Regions 3, 4 and 5 were completely methylated 
in SaOS-2. Region 6 was partially methylated in SaOS-2. In SaOS-2, only one full 
Region 6 clone was sequenced. This clone was unmethylated for CpGs 1-15 and 
methylated at CpGs 16-26. However, using a different primer set that amplified CpGs 23-
26 in Region 6, ten clones were sequenced of SaOS-2. Of these ten clones, five were 
completed methylated, four were completely unmethylated, one showed a single 
unmethylated CpG of the four CpGs (Figure 8).  
In this study, we found similar results in U20S. Regions 1 and 2 were completely 
unmethylated. Regions 3, 4 and 5 were mostly methylated yet a few CpGs in each region 
were unmethylated. This similarity between U20S and SaOS-2 suggest that sites of DNA 
methylation during osteosarcoma progression are unique to this cancer type. Region 6 
had differing levels of methylation especially at CpGs 23-26. As a comparison in Region 
6, SaOS-2 was 61.4% methylated in CpGs 23-26, whereas U20S was 25% methylated 
based on the all clones that were sequenced (Figure 8). These results show that the 
Promoter B start of transcription and Exon 1β region are less methylated in U20S 
osteosarcoma than in SaOS-2. The level of methylation at Region 6 is negatively 
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correlated with Promoter B activity. We found that Promoter B is more active in U20S 
cells, in comparison to SaOS-2 cells and U20S cells is less methylated in Region 6. This 
relationship suggests that even low methylation in Region 6 may influence Promoter B 
transcription levels.   
 
 
Figure 8. Methylation Status in U20S and SaOS-2 CpG Island Region 6.  Each circle 
represents a CpG within that particular CpG island region. The numbers indicate relative 
base pair within the intron sequence with the first base pair of the intron as number 1. 
Numbers correspond to the CpG location within the region. Percent are methylated CpGs 
divided by total CpGs in CpGs 23-26 of all clones. Closed circle = methylated CpG; open 
circle = unmethylated CpG. Each row is an individual sequenced clone.  
 
 
 Regions 1 and 2 in osteosarcoma are possibly unmethylated due to its proximity 
to the Promoter A Exon 1 (Figure 5).  Regions 3, 4 and 5 may or may not be involved in 
the regulation of Promoter B. The results of Vaidya (2013) do not provide a clear answer. 
When SaOs-2 cells were treated with 5-aza-deoxycytidine, which removes methyl groups 
from DNA, the level of Promoter B transcripts increased dramatically.  Bisulfite 
sequencing showed that few of the methylated groups in Region 3, 4, 5 and 6 were 
altered. It would be expected that more CpGs would be demethylated in Region 6, but 
this was not the case.  
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  It is puzzling that U20S cells have such low levels of methylation in Region 6 
CpGs 23-26. Although the number of Promoter B transcripts (per µg of RNA) is higher 
in U20S cells in comparison to SaOS-2 cells, transcript levels are reduced relative to 
normal osteoblasts. This suggests that Promoter B transcription is reduce in U20S in spite 
of the lower level of methylation in Region 6. Another possibility is that methylation of 
Regions 3, 4, or 5 is also impacting U20S Promoter B transcription, as these regions may 
include enhancers. Also, as our results show changes in histone modifications is likely 
contributing to reduced Promoter B transcription.   
Reduced H3K4me3 in Promoter B Region 6 of U20S Cells 
 Three different histone modifications, H3K4me3, H3K9me3 and H3K27me3 
were examined for enrichment at Promoter A, Promoter B, and Regions 3, 4, 5 (Figures 6 
and 7). RNA polymerase II was used as a positive control for actively transcribed genes. 
A GAPDH primer was included in the ChIP assay as a gene that is highly expressed.  
  H3K27me3 is associated with transcriptional repression and promotes chromatin 
compaction (Rose & Klose, 2014). In somatic and cancer cells, H3K27me3 was found to 
overlap with areas of DNA methylation (Schlesinger et al., 2007; Brinkman et al., 2012). 
One prediction is that Promoter A region of SaOS-2 and U20S cells would be less 
enriched in H3K27me3 than Promoter B. Also, Regions 3, 4 and 5 would be enriched in 
H3K27me3. Our results show no difference in H3K27me3 enrichment between Promoter 
A and Promoter B in U20S or in SaOS-2. Regions 3 and 4 had higher levels of 
enrichment in H3K27me3 in comparison to GAPDH. These results indicate that 
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H3K27me3 is not responsible for the reduction in Promoter B activity in U20S or SaOS-
2.  
 H3K9me3 is generally associated with repressed chromatin and has a role in de 
novo methylation of heterochromatin regions (Gordon et al. 2013). It would not be 
expected to associate with Promoters A and B but may possibly be associated with 
Regions 3, 4 and 5. The results show that H3K9me3 is not more enriched at Promoter A 
and Promoter B than measured at GAPDH in U20S cells. This finding suggests that 
H3K9me3 is not associated with the decrease in Promoter B expression in U20S cells. 
Region 3, 4 and 5 show no greater enrichment in H3K9me3 than GAPDH, indicating 
these sequence regions are not heterochromatic.  
H3K4me3 is associated with active promoters and is found in regions of 
unmethylated DNA (Rose & Klose, 2014). It would be predicted that H3K4me3 would 
be more enriched at Promoter A than Promoter B and not associated with Regions 3, 4, 
and 5. H3K4me3 showed higher enrichment in Promoter A than Promoter B of U20S 
cells. The reduction in H3K4me3 at Promoter B could, in part, explain the decrease in 
Promoter B activity in U20S cells. A possible mechanism is that with reduced H3K4me3, 
the DNA methyltransferase Dnmt3 a/b, could de novo methylate CpGs in the Region 6. It 
appears as if the U20S Promoter B Region 6 is in the process of being de novo 
methylated. Regions 3, 4, 5 had low levels of H3K4me3 enrichment similar to Promoter 
B and lower than Promoter A. As expected, GAPDH had high levels of H3K4me3 
enrichment.  
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Both Promoter A and B are active in the U20S cells, so some RNA polymerase II 
is expected to be binding to these promoters. Overall our results confirm this prediction, 
although the Promoter B B1probe gave a higher value of enrichment. RNA polymerase II 
was, as expected, highly enriched for GAPDH.  
In the SaOS-2 cells we found that H3K27me3 is not enriched in either Promoters 
A or B. These results are consistent with the U20S results.  
The U20S ChIP data results suggest that the loss of H3K4me3is involved in the 
decrease in Promoter B transcripts. There seems to be a decrease in H3K4me3 when 
moving across the WNT5A intron 1. In Promoter A, there was enrichment of H3k4me3 
(Figure 6E). In Regions 3, 4, 5, there is a progressive decrease in H3K4me3 enrichment 
(Figure 6F). There are lower levels of H3K4me3 enrichment at Promoter B than at the 
Promoter A region (Figure 6E). A possible model for the decrease in Promoter B 
transcripts is the loss of methylation at H3K4 leads to both a decrease in transcription 
factor recruitment and increased DNA methylation through the binding of DNA 
methyltransferases (Figure 9). The loss of H3K4 methylation at the Promoter B region 
could then lead to the DNA methylation patterns seen in Figure 5 for Regions 3, 4, 5 and 
6 of U20S. The combination of H3K4 methylation loss and DNA methylation could be 
the reason for the decrease in Promoter B transcripts.  
 
55 
 
 
Figure 9. Model for Histone Modification and DNA Methylation related to 
Promoter B Transcription. A. The methylation of H3K4me3 leads to the recruitment of 
transcription factors (TF). This then leads to an increase in transcription through the 
recruitment of RNA polymerase II and other transcriptional elements. B. The loss of 
H3K4me3 allows for the binding of DNA methyltransferase 3L (Dnmt 3L), which forms 
a complex with DNA methyltransferase 3a/b (Dnmt3a/b). The Dnmt complex then 
methylates the DNA, blocking transcription.  
 
 
Overall, the ChIP assays suggest that a reduction in the activating histone, 
H3K4me3 at the Promoter B Region 6, is associated with reduced Promoter B activity. It 
may also be responsible for the increased DNA methylation at Region 6. It will be 
important to complete the ChIP assay in SaOS-2 to confirm that Promoter B lacks 
H3K4me3. This does not explain the methylation of Regions 3, 4 and 5 and their role, if 
any, in regulating WNT5A Promoter A and Promoter B expression. Nor do these findings 
reveal the functional role of the WNT5A Promoter B protein isoform in osteoblast cell 
function. 
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